0002001011-24-000027.txt : 20240229
0002001011-24-000027.hdr.sgml : 20240229
20240229184956
ACCESSION NUMBER: 0002001011-24-000027
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240227
FILED AS OF DATE: 20240229
DATE AS OF CHANGE: 20240229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Davis Todd C
CENTRAL INDEX KEY: 0001392029
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 24706120
MAIL ADDRESS:
STREET 1: 11119 NORTH TORREY PINES ROAD
STREET 2: SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-02-27
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001392029
Davis Todd C
3911 SORRENTO VALLEY, SUITE 110
SAN DIEGO
CA
92121
1
1
0
0
CHIEF EXECUTIVE OFFICER
0
Common Stock
2024-02-27
4
A
0
32436
0.0
A
104145
D
Employee Stock Option (right to buy)
89.2
2024-02-27
4
A
0
131723
0.0
A
2034-02-27
Common Stock
131723
131723
D
Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2025; February 15, 2026; and February 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter.
By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis
2024-02-29